Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study
Research output: Contribution to journal › Journal article › Research › peer-review
Nalmefene is an orally administered competitive opioid receptor antagonist targeted at reducing alcohol consumption in alcohol-dependent patients. As part of the regulatory requirements for drug approval, the potential of novel compounds for causing unwanted proarrhythmia should be studied in a thoroughly designed clinical QT/corrected QT (QTc) study (International Conference on Harmonisation [ICH] E14 guideline).
| Original language | English |
|---|---|
| Journal | Clinical Drug Investigation |
| Volume | 31 |
| Issue number | 11 |
| Pages (from-to) | 799-811 |
| Number of pages | 13 |
| ISSN | 1173-2563 |
| DOIs | |
| Publication status | Published - 2011 |
- Adult, Anti-Infective Agents, Arrhythmias, Cardiac, Aza Compounds, Biomarkers, Pharmacological, Dose-Response Relationship, Drug, Double-Blind Method, Electrocardiography, Female, Guidelines as Topic, Heart Rate, Humans, Long QT Syndrome, Male, Naltrexone, Narcotic Antagonists, Placebos, Prospective Studies, Quinolines, Treatment Outcome, Young Adult
Research areas
ID: 48052162